PMCB
PharmaCyte Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.49
−0.98%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -70.7%
- EBIT
- -56.6%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +92.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- -21.2%
- EBIT
- -56.6%
- Net income
- —
- EPS
- —
- Free cash flow
- -73.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Apr 1, 2026